Disease Landscape and Forecast Insights

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with EGFR- and ALK-positive tumors generally receive…

The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…

The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…

Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…

The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. The immune checkpoint inhibitors Tecentriq (Roche; FDA approved in 2019) and Imfinzi (…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…

Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…